Wedbush Maintains Outperform on Black Diamond Therapeutic, Raises Price Target to $14

Benzinga Newsdesk www.benzinga.com Positive 89.5%

Neg 0% Neu 0% Pos 89.5%

Wedbush analyst Robert Driscoll maintains Black Diamond Therapeutic (NASDAQ:BDTX) with a Outperform and raises the price target from $13 to $14.